Video

More Follow-Up Suggested After Removing Pancreatic Cysts

Author(s):

Data suggests a more scrutinized follow-up period following surgery.

New research suggests closer and more expansive follow-up for patients who had pancreatic cysts surgically removed.

In data presented at the annual American College of Gastroenterology (ACG) 2020 virtual meeting, a team of doctors from the Cleveland Clinic described the post-surgical course of pancreatic cyst patients, while evaluating the rates and predictors of recurrent cysts, high-risk, and malignant transformation over a 5 year review of existing data.

In an interview with HCPLive®, Mohannad Abou Saleh, MD and Prabhleen Chahal, MD, explained how the review might ultimately result in a change in the guidelines to closely monitor these patients for longer periods of time.

In the cohort, the investigators examined data from 104 patients who underwent surgical intervention for pancreatic cysts with 37 (37.4%) cases undergoing pancreaticoduodenectomy and 62 (62.6%) undergoing distal pancreatectomy.

At the one-year mark following surgery, 34.5% had recent cysts with 5.1% with high-risk transformation and 11.7% malignant transformation. By year 5, these rates increased to 64.8%, 13.7%, and 19%, respectively.

The overall mortality rate was 13.5%, with 5.8% related to pancreatic causes over the 5 year review period.

Chahal explained how this study shows how most guidelines and practices should be constantly updated and examined as more information and data comes out.

Related Videos
Ladan Zand, MD: Evaluating Obinutuzumab in Primary FSGS and Further Research
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Kishore Iyer, MD , MBBS | Credit: Kishore Iyer on LinkedIn
Evan Dellon, MD, MPH | Credit: UNC Chapel Hill
Marlyn Mayo, MD | Credit: ACG
Kishore Iyer, MD, MBBS | Credit: Kishore Iyer on LinkedIn
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
Bruce Sands, MD | Credit: Alimentiv
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
© 2024 MJH Life Sciences

All rights reserved.